Reema Patel
Overview
Explore the profile of Reema Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
285
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elghawy O, Patel R, Mullapudi A, Kurian M, Wang J, Xu J, et al.
J Chemother
. 2025 Jan;
1-7.
PMID: 39773445
Immune checkpoint inhibitors (ICIs) have shown promise in the treatment of gastric and oesophageal cancers (GEC). Despite their promising efficacy, ICIs have been associated with unique side effects known as...
2.
Wang M, Sussman J, Xu J, Patel R, Elghawy O, Rawla P
Life (Basel)
. 2025 Jan;
14(12.
PMID: 39768352
Polycomb repressive complex 2 (PRC2) is known to regulate gene expression and chromatin structure as it methylates H3K27, resulting in gene silencing. Studies have shown that PRC2 has dual functions...
3.
Cassim E, McDonald H, Harper M, Chen Q, Lin M, Patel R, et al.
J Appalach Health
. 2024 Dec;
6(1-2):6-20.
PMID: 39640244
Introduction: Rates of cancer mortality in Appalachian Kentucky is among the highest in the nation. It is unknown whether geographic location of treatment for pancreatic ductal adenocarcinoma (PDAC), one of...
4.
Gupta G, Patel R, Akce M, Chauhan A
Chin Clin Oncol
. 2024 Nov;
13(5):80.
PMID: 39496550
No abstract available.
5.
Elghawy O, Barsouk A, Patel R, Reed-Guy L, Wang J, Xu J, et al.
Immunotherapy
. 2024 Oct;
16(16-17):1069-1078.
PMID: 39392156
Immune-checkpoint inhibitors (ICIs) have revolutionized treatment of metastatic head and neck squamous cell carcinomas (HNSCCs). Our goal was to assess for an association between immune-related adverse events (irAEs) and clinical...
6.
Donawa A, Powell C, Wang R, Chih M, Patel R, Zinner R, et al.
JMIR Form Res
. 2024 Sep;
8:e57801.
PMID: 39326043
Background: Despite the increased accessibility and availability of technology in recent years, equality and access to health-related technology remain limited to some demographics. In particular, patients who are older or...
7.
Shah S, Lai J, Basuli F, Martinez-Orengo N, Patel R, Turner M, et al.
Sci Transl Med
. 2024 Aug;
16(760):eadl5934.
PMID: 39141701
The global incidence of invasive fungal infections (IFIs) has increased over the past few decades, mainly in immunocompromised patients, and is associated with high mortality and morbidity. is one of...
8.
McDonald H, Kennedy A, Solomon A, Williams C, Reagan A, Cassim E, et al.
Ann Surg Oncol
. 2024 Aug;
31(12):7705-7712.
PMID: 39133448
Background: Guidelines now recommend universal germline genetic testing (GGT) for all pancreatic ductal adenocarcinoma (PDAC) patients. Testing provides information on actionable pathogenic variants and guides management of patients and family....
9.
Patel R, Elghawy O, Gibbs A, Gupta S, Kaur V
Cancer Rep (Hoboken)
. 2024 Jul;
7(7):e2110.
PMID: 39051557
Background: The advent of immune checkpoint inhibitors (ICIs) represented a significant breakthrough in cancer therapy. Recently, the combined use of atezolizumab and bevacizumab was approved as first-line treatment for unresectable...
10.
Patel R, Korenman S, Weimer A, Grock S
Cureus
. 2024 Jul;
16(6):e62262.
PMID: 39006737
Gender-affirming hormone therapy for assigned male at birth (AMAB) individuals with gender incongruence typically consists of estradiol with or without an anti-androgen to achieve physical changes and psychological benefits. However,...